



# Veklury<sup>®</sup> (remdesivir) Flushing IV Line

This document is in response to your request for information regarding flushing the IV line after Veklury<sup>®</sup> (remdesivir [RDV]) infusion is complete.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

**The full indication, important safety information, and boxed warnings are available at: [www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi).**

---

## Available Data on Flushing IV Line After RDV Infusion

After infusion of RDV is complete, it is best practice to **flush the IV line with sufficient volume of 0.9% sodium chloride at the same infusion rate** to ensure that all the RDV solution has been administered. The flush volume should be greater than the priming volume of the infusion tubing to ensure that all the RDV solution has been administered.<sup>1</sup>

Please refer to the local label for additional instructions for the preparation and administration of RDV, if applicable.

---

## Reference

1. Gilead Sciences Inc. Data on File.

---

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Veklury US Prescribing Information available at:

[www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi).

## Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 [www.askgileadmedical.com](http://www.askgileadmedical.com)

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 [www.gilead.com/utility/contact/report-an-adverse-event](http://www.gilead.com/utility/contact/report-an-adverse-event)

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [gilead.privacy@gilead.com](mailto:gilead.privacy@gilead.com).

VEKLURY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.